drugset / Trial / NCT00545129

A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

NCT00545129

Phase 2 Completed 59 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.

Timeline

Start
2009-04-29
Primary completion
2011-12-24
Completion
2012-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 10 mg Intravenous

Indications